This week, there were 15 investments and financings in the field of medicine and health, involving biological reagents, molecular diagnosis and other fields

People’s Daily Health Client Zhao Mengmeng

According to the incomplete statistics of the People’s Daily Health Client, this week (October 24-28), there were 15 investment and financing events in the medical and health field across the country. Among them, there are 6 cases that exceed 100 million yuan, and a number of pharmaceutical companies such as Pushcon, Colinbree, and AiRemedy have obtained financing of more than 100 million yuan, involving biological reagents, molecular diagnostics and other related fields.

Biomedical field

Jiyuan Gene: Completed the A round of financing of 100 million yuan to promote the research and development of tumor treatment products

On October 24, Hangzhou Jiyuan Gene Technology Co., Ltd. completed the A round of financing of RMB 100 million invested by Vivo Capital. The funds raised will be used to advance the research and development of the company’s new generation of generic off-the-shelf cellular immuno-oncology products.

Jiyuan Gene was established in 2020 as an innovative biotechnology company. Jiyuan Gene adopts the world’s leading genetic engineering and cell engineering technology, and is committed to the development and industrialization of general off-the-shelf cellular immunotherapy products.

Einuo Micropharmaceutical: Received C+ round of financing for new drug research and development

On October 27th, the developer of innovative tumor immunotherapy drugs Einuo Micropharmaceutical announced the signing of the C+ round of financing with the first batch of investors. This round of financing was led by China Merchants China Fund Co., Ltd., Wuzhong Biomedical Industry Development Fund, and Gandao Fund. Participate in investment.

The funds raised from this financing will be mainly used to support the clinical trials of single drugs and combination drugs in China and the United States for the company’s three product pipelines that have entered the clinical stage, the subsequent IND filing of oncolytic virus and exosome product pipelines, and Drug development and validation of new product candidates for the OvPENS platform.

Established in May 2015, Shenzhen Einuowei Pharmaceutical Technology Co., Ltd. is a platform-based biotechnology company focusing on the development of clinical demand-oriented anti-tumor and other disease drug carriers. It is committed to precise genetic engineering through independent intellectual property rights. technology, using the natural drug delivery mechanism to develop a new generation of replicating and non-replicating herpesvirus vectors and exosome delivery vectors.

Up to now, the first batch of three oncolytic virus products of Innomicro has been undergoing Phase I and Phase II clinical studies in both China and the United States, including single drug and combined use.

Chuangxin International: Received nearly 100 million yuan in Series A financing to accelerate the research and development of organoid technology and industrial transformation

On October 28, Chuangxin International completed a Pre-B round of financing of RMB 100 million. This round of financing was led by Dachen Caizhi, followed by Guangzhou Financial Holdings, Guangzhou Development Zone Fund, Wanlian Securities, Zhonghe Anke, and Qudao Assets and other original investment institutions continued to make additional investments.

Chuangxin International was established in Macau in 2016 and moved from Macau to Guangzhou in 2017. Its headquarter is located in the Guangzhou Development Zone Accelerator. It is an innovative biomedical enterprise with organoids as its core technology. It consists of the China-Europe Organoid Research Institute and a clinical third-party testing center.

At present, Chuangxin International has a number of organoid patents, and its business covers many provinces and regions across the country. It mainly provides organoid culture detection systems and new drug research and development, and has established R&D centers in Beijing, Guangzhou, Shanghai, Macau and Milan, Italy. In addition, Chuangxin International is also building a whole industry chain of organoids around the three directions of clinical individualized treatment of organoids, drug research and development, and regenerative medicine.

Medical device field

Changde Medical: Completed tens of millions of yuan in angel round financing to create a complete solution for peripheral intervention

On October 24, Shanghai Changde Medical Technology Co., Ltd. completed an angel round of financing of tens of millions of yuan. This round of financing was led by Legend Capital and followed by Shanghai Xinyue Jiupeng Enterprise Consulting Center (Limited Partnership). The financing amount will be used for the research and development of the company’s peripheral intervention pipeline.

Changde Medical was established in November 2021. The company is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices. For peripheral arteriovenous diseases, it develops drug balloons, catheters, stents, thrombus removal equipment and other products.

The company simultaneously carries out independent research and development and external cooperation, and further improves the product line by introducing innovative products. Recently, the company has reached a cooperation with the American company Control Medical to introduce its Control mechanical thrombus removal system. This product can be used to remove thrombus in peripheral blood vessels and coronary arteries. It can be manually controlled by doctors to achieve efficient and controllable thrombus aspiration. It has been approved by the FDA and has been used in thousands of patients.

Pushcom Bio: Completed C+ round of financing over 100 million yuan to accelerate the layout of microfluidic POCT platform-based enterprises

On October 24th, Zhejiang Pushikang Biotechnology Co., Ltd. completed a C+ round of financing of over 100 million yuan. This round of financing was led by October Capital, followed by Jiji Venture Capital and Changan Huitong, and the old shareholder Yinglian Health continued to increase its investment.

Founded in 2014, Pushcom Bio is a centrifugal microfluidic platform-based enterprise, focusing on the field of critical illness and chronic disease management and testing, and developing microfluidic technology products that can cover multiple scenarios and multiple departments. The company takes the three-in-one systematic R&D capability of discs + reagents + instruments as the core, and has developed POCT full-platform products covering coagulation, biochemistry, luminescence, molecules and other fields according to the needs of different clinical scenarios.

This round of financing will further accelerate the pipeline expansion of Pushcon’s centrifugal microfluidic platform products focusing on critical and critical illness + chronic disease management, and accelerate the overseas sales layout. .

Shenluo Medical: Completed the B round of financing of nearly 100 million yuan, and made breakthroughs in a number of neuromodulation innovative devices

On October 24, Hangzhou Shenluo Medical Technology Co., Ltd., an innovative company in the field of neuromodulation, successfully completed its Series B financing of nearly 100 million yuan. This round of financing was led by SDIC Chuanghe, and the old shareholder Boyuan Capital continued to invest more.

This round of financing will be used for new product development, clinical research, registration applications, and chip iterations. In the past year, Shenluo Medical has completed three rounds of financing exceeding 100 million yuan.

Founded in 2018, Shenluo Medical focuses on the independent research and development and production of medical devices in the field of implantable neuromodulation. It is committed to continuously providing more advanced and effective treatment methods for doctors and patients, and is committed to improving more refractory diseases. patients’ quality of life.

In addition, Shenluo Medical is developing neuromodulation products with different technical paths and different application scenarios. At the same time, the new generation of products of Shenluo Medical will use self-developed chips.

medical services

Colin Bree: Completed nearly 200 million yuan in Series C financing to accelerate the upgrading of industrial digital intelligence

On October 25th, the leading medical big data company Colin Brie completed nearly 200 million yuan in Series C financing, led by Legend Capital and followed by Guohe Investment.

After this round of financing, Colinbree will continue to cultivate in the field of medical big data, explore the deep integration of big data and AI in the medical industry, promote the research and development of underlying technologies and scenario-based applications, and accelerate the upgrading of industrial digital intelligence.

Founded in 2013, Colinbree is a high-tech enterprise focusing on hospital information integration platforms, medical big data centers, and hospital big data application services. It is a leading medical big data service provider in China. As a high-tech enterprise focusing on medical big data middle-end, digitization and intelligent application services, Colinbree will be shortlisted as a “little giant” enterprise specializing in the Ministry of Industry and Information Technology in 2022.

Xushui Interconnection: Completed tens of millions of yuan in Series A financing, providing medical equipment AIoT and digital applications

On October 28, Beijing Xushui Internet Technology Co., Ltd. completed tens of millions of yuan in Series A financing, led by Huimei Capital, and pre-A round led by Fang Yuanyi Capital.

Founded in 2016, Xushui Interconnection is a hard technology company focusing on the application of artificial intelligence and Internet of Things in medical equipment. It relies on self-developed digital twin technology to realize the transformation of intelligent management of medical equipment, and builds a normalized digitalization of medical equipment for tertiary hospitals. The application platform uses real data to promote the implementation of intelligent management of hospitals and promote high-quality connotative development.

The proceeds of this round of financing will be used to promote the company’s research and development in the field of medical equipment AIoT and digital applications, and accelerate the commercialization of related results in hospital customers.